Can Moderna Repeat COVID-19 Success In Influenza Market?
First Subject Dosed In Flu Vaccine Trial
The company could have a significant competitive position thanks to the ability to rapidly develop and combine vaccines using mRNA technology.
You may also be interested in...
The French drug maker isn’t moving its mRNA COVID-19 vaccine into Phase III, instead focusing on a GSK-partnered protein SARS-CoV-2 vaccine and applying mRNA technology elsewhere.
AstraZeneca and Moderna disclosed clinical and preclinical evidence that their COVID-19 vaccines, Vaxzevria and mRNA-1273, provide protection against the B.1.617.2 strain.
A rush of additional orders from countries around the world has boosted the company’s prospects, and fueled its ambitions beyond COVID-19.